{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:50:13Z","timestamp":1785840613058,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health National Cancer Institute","award":["CA180888"],"award-info":[{"award-number":["CA180888"]}]},{"name":"National Institutes of Health National Cancer Institute","award":["CA180819"],"award-info":[{"award-number":["CA180819"]}]},{"name":"National Institutes of Health National Cancer Institute","award":["CA180858"],"award-info":[{"award-number":["CA180858"]}]},{"name":"National Institutes of Health National Cancer Institute","award":["CA180801"],"award-info":[{"award-number":["CA180801"]}]},{"name":"National Institutes of Health National Cancer Institute","award":["CA180846"],"award-info":[{"award-number":["CA180846"]}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jtho.2017.05.021","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:47:19Z","timestamp":1496796439000},"page":"1299-1308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)"],"prefix":"10.1016","volume":"12","author":[{"given":"Anne S.","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Kalemkerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary W.","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2017.05.021_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a\u00a0randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.021_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E","article-title":"Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in\u00a0vitro and in\u00a0vivo","volume":"178","author":"Langerak","year":"1996","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2017.05.021_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma","volume":"435","author":"Konig","year":"1999","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2017.05.021_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000087376","article-title":"Serum PDGF-AB in pleural mesothelioma","volume":"26","author":"Filiberti","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jtho.2017.05.021_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type\u00a0C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2017.05.021_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2017.05.021_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1159\/000176386","article-title":"Mesothelioma cell proliferation through autocrine activation of PDGF-betabeta receptor","volume":"29","author":"Honda","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jtho.2017.05.021_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":"Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2017.05.021_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0026-895X(25)09719-6","article-title":"Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme","volume":"46","author":"Dorai","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jtho.2017.05.021_bib11","first-page":"6180","article-title":"Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines","volume":"47","author":"Gerwin","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.021_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/A:1006542301794","article-title":"Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction","volume":"16","author":"Klominek","year":"1998","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jtho.2017.05.021_bib13","first-page":"301","article-title":"Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma","volume":"52","author":"Walker","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.021_bib14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","article-title":"Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network","volume":"179","author":"Li","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2017.05.021_bib15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-07-1388","article-title":"Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts","volume":"14","author":"Bertino","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2017.05.021_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2017.05.021_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","article-title":"Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma","volume":"15","author":"Tsao","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.021_bib18","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II\u00a0trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A\u00a0multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2017.05.021_bib20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br\u00a0J Cancer"},{"key":"10.1016\/j.jtho.2017.05.021_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor\u00a0vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.jtho.2017.05.021_bib22","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/JTO.0b013e318208c83d","article-title":"A\u00a0practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria","volume":"6","author":"Tsao","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/SPC.0b013e32835ec861","article-title":"Mechanisms of TKI-induced diarrhea in cancer patients","volume":"7","author":"Bowen","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.jtho.2017.05.021_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejca.2013.11.032","article-title":"Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29","volume":"50","author":"Laurie","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2017.05.021_bib27","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2012.42.6031","article-title":"Cediranib plus FOLFOX\/CAPOX versus placebo plus FOLFOX\/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)","volume":"30","author":"Hoff","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"6","author":"Symonds","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2017.05.021_bib29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer\u00a0(ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2017.05.021_bib30","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2017.05.021_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641730429X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641730429X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:40:42Z","timestamp":1750293642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641730429X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S155608641730429X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2017.05.021","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}